Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
ID | Components | Size |
EP155-C01 | High-bind Plate | 1 plate |
EP155-C02 | Human Integrin α 4 β 7 | 25 μg |
EP155-C03 | Biotinylated Human MAdCAM-1 | 10 μg |
EP155-C04 | Anti-Integrin α 4 β 7 Neutralizing Antibody | 20 μg |
EP155-C05 | Streptavidin-HRP | 5 μg |
EP155-C06 | Coating Buffer | 12 mL |
EP155-C07 | 10xWashing Buffer | 50 mL |
EP155-C08 | Blocking Buffer | 50 mL |
EP155-C09 | Substrate Solution | 12 mL |
EP155-C10 | Stop Solution | 7 mL |
EP155-C11 | 1mol/L CaCl₂ | 1.5 mL |
EP155-C12 | 1mol/L MgCl₂ | 1.5 mL |
EP155-C13 | 1mol/L MnCl₂ | 1.5 mL |
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
INHIBITION OF Integrin α 4 β 7: MAdCAM-1 [Biotinylated] BINDING BY ANTI-Integrin α 4 β 7 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-Integrin α 4 β 7 Neutralizing antibody (Catalog # EP155-C04) (1:1 serial dilution, from 5 μg/mL to 0.0098μg/mL) was added into Integrin α 4 β 7: Biotinylated MAdCAM-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
INHIBITION OF Integrin α 4 β 7: MAdCAM-1 [Biotinylated] BINDING BY selective α4 integrin antagonist
Serial dilutions of selective α4 integrin antagonist (1:1 serial dilution, from 10 μg/mL to 0.1526μg/mL) was added into Integrin α 4 β 7: Biotinylated MAdCAM-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Carotegrast methyl | AJM-300 | Approved | Ea Pharma, Eisai Co Ltd | Carogra | Japan | Colitis, Ulcerative | Ea Pharma Co Ltd | 2022-03-28 | Colitis, Ulcerative | Details |
Vedolizumab | MLN-0002; LPD-02; MLN-002; MLN-02; LDP-02 | Approved | Millennium Pharmaceuticals Inc | Entyvio, Entyvio Pen, Kynteles, 安吉优 | United States | Colitis, Ulcerative; Crohn Disease | Takeda Pharmaceuticals USA Inc | 2014-05-20 | Pediatric ulcerative colitis; Melanoma; Carcinoma, Non-Small-Cell Lung; Crohn Disease; Gastritis; Urogenital Neoplasms; Colitis, Ulcerative; Cholangitis, Sclerosing; Celiac Disease; Solid tumours; Colitis; Neoplasms; Pouchitis; Pediatric Crohn's disease; Inflammatory Bowel Diseases; HIV Infections; Hematopoietic stem cell transplantation (HSCT) | Details |
Natalizumab biosimilar(Polpharma Biologics) | PB-006; DST-356A1 | Approved | Polpharma Biologics Sa | Tyruko | United States | Multiple Sclerosis; Crohn Disease | Sandoz Inc | 2023-08-24 | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Crohn Disease | Details |
Natalizumab | BG-0002; TY-21.6; AN-10022; BG-00002; AN-100226; BG-0002-E | Approved | Biogen Inc, Perrigo Llc | Tysabri, Antegran, Antegren | United States | Crohn Disease; Multiple Sclerosis | Biogen Idec | 2004-11-23 | Multiple Sclerosis, Relapsing-Remitting; Epilepsies, Partial; Arthritis, Rheumatoid; Graft vs Host Disease; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis; Multiple Myeloma; Myositis, Inclusion Body; Demyelinating Diseases; Ischemic Stroke; Crohn Disease | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Etrolizumab | PRO-145223; rhuMAb-Beta7; R-7413; RG-7413 | Phase 3 Clinical | Genentech Inc | Colitis, Ulcerative; Crohn Disease | Details |
Vedolizumab biosimilar (Polpharma Biologics) | PB-016 | Phase 3 Clinical | Polpharma Biologics Sa | Pouchitis; Colitis, Ulcerative; Crohn Disease | Details |
Vedolizumab biosimilar (Alvotech) | AVT-16; AVT16 | Phase 3 Clinical | Alvotech Swiss Ag | Immune System Diseases; Colitis, Ulcerative | Details |
Natalizumab biosimilar (GENERIUM Pharmaceuticals) | GNR-093 | Phase 3 Clinical | Generium Pharmaceuticals | Multiple Sclerosis | Details |
MORF-057 | MORF-057 | Phase 2 Clinical | Morphic Therapeutic Inc | Inflammatory Bowel Diseases; Colitis, Ulcerative; Crohn Disease | Details |
PN-10943 | PN-10943-A; PN-10943; PN-943 | Phase 2 Clinical | Protagonist Therapeutics Inc | Colitis, Ulcerative | Details |
GS-1427 | GS-1427 | Phase 2 Clinical | Gilead Sciences Sl | Inflammatory Bowel Diseases; Colitis, Ulcerative | Details |
ABBV-382 | ABBV-382 | Phase 2 Clinical | Abbvie Inc | HIV Infections; Crohn Disease | Details |
PTG-100 | PTG-100 | Phase 1 Clinical | Protagonist Therapeutics Inc | Celiac Disease; Colitis, Ulcerative | Details |
EA-1080 | NSHO-101; EA-1080 | Phase 1 Clinical | Ea Pharma | Inflammatory Bowel Diseases | Details |
SPY-001 | SPY001; SPY-001; PR-011; PR011; SPY001-001 | Phase 1 Clinical | Paragon Therapeutics Inc | Inflammatory Bowel Diseases | Details |
This web search service is supported by Google Inc.